rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    NYXH
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Nyxoah Obtains Default Decision Against Inspire Medical Systems in Unified Patent Court Case

      INSIDE INFORMATIONREGULATED INFORMATION Nyxoah Obtains Default Decision Against Inspire Medical Systems in Unified Patent Court Case Mont-Saint-Guibert, Belgium – November 18, 2026, 8:00 am CET / 2:00 am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Court of First Instance of the Unified Patent Court (UPC

      20h agoYahoo FinanceNYXH
      Nyxoah SA (NYXH) Q3 2026 Earnings Call Highlights: U.S. ...

      Nyxoah SA (NYXH) posted 29% sequential U.S. revenue growth and strong AXIS study results, but trimmed its 2026 outlook as it awaits FDA review of the Genio CCC indication.

      Nov 6Yahoo FinanceNYXH
      Nyxoah SA (NYXH) Reports Q3 Loss, Lags Revenue Estimates
      Nov 6Yahoo FinanceNYXH
      Nyxoah Q3 2026 Earnings Call Transcript
      Nov 5BenzingaNYXH
      Nyxoah (ENXTBR:NYXH) Stock Sees Fair Value Falls After Q2 Analyst Target Cuts
      Oct 22Yahoo FinanceNYXH
      Nyxoah Update (NASDAQ:NYXH)
      Oct 21Seeking AlphaNYXH
      Here's Why Nyxoah (NYXH) Could be Great Choice for a Bottom Fisher

      Nyxoah (NYXH) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

      Oct 20Yahoo FinanceNYXH
      Nyxoah Announces Preliminary Results for the Third Quarter of 2026 and Adjusts Revenue Guidance for 2026
      Oct 19Yahoo FinanceNYXH
      Nyxoah presents 12-month data for sleep apnea device study
      Oct 15Investing.comNYXH
      Full 12-Month Data from the ACCCESS U.S. Pivotal Study in Complete Concentric Collapse Patients Presented at ISSS 2026

      Full 12-Month Data from the ACCCESS U.S. Pivotal Study in Complete Concentric Collapse Patients Presented at ISSS 2026 Genio® bilateral stimulation delivered a 74.3% median reduction in AHI at 12 months, with no device- or procedure-related serious adverse events PMA supplement submitted to the FDA to expand Genio’s indication to CCC patients Mont-Saint-Guibert, Belgium – October 15, 2026, 10:05 pm CET / 4:05 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medic

      Oct 15Yahoo FinanceNYXH
      Nyxoah: Label Expansion Set To Unlock A Monopoly In A Billion Dollar Market.
      Oct 5Seeking AlphaNYXH
      Nyxoah Taps Former Teleflex Chief Liam Kelly to Lead U.S.-Focused Growth Drive

      Detailed price information for Nyxoah S A (NYXH-Q) from The Globe and Mail including charting and trades.

      Sep 29The Globe and MailNYXHTFX
      Nyxoah Names Liam Kelly as Chief Executive

      Nyxoah (NYXH) appointed Liam Kelly as chief executive officer, starting Oct. 1, succeeding Olivier T

      Sep 28Yahoo FinanceNYXH
      Nyxoah Names Former CFO Loïc Moreau as Interim Finance Chief, Reaffirms 2026 Guidance

      Detailed price information for Nyxoah S A (NYXH-Q) from The Globe and Mail including charting and trades.

      Sep 23The Globe and MailNYXH
      Nyxoah shares fall after CFO departure announcement
      Sep 21Investing.comNYXH
      Nyxoah announces CFO transition, reaffirms 2026 guidance
      Sep 21Investing.comNYXH
      Nyxoah Announces Chief Financial Officer Transition
      Sep 21Yahoo FinanceNYXH
      Cantor Fitzgerald reiterates Nyxoah stock Overweight rating at $6
      Sep 15Investing.comNYXH
      Nyxoah (NYXH) Begins BREATHE Study. Can Real-World Evidence Drive Genio Adoption?

      Nyxoah SA (NASDAQ:NYXH) announced the first patient implantation in BREATHE on September 7. The prospective, single-arm U.S. post-approval study will evaluate Genio hypoglossal-nerve stimulation in adults aged 22 or older with moderate to severe obstructive sleep apnea for whom standard-care treatments have failed, cannot be tolerated, or are unsuitable. Plans call for up to 229 […]

      Sep 10Yahoo FinanceNYXH
      Nyxoah Stock Down Despite First Genio Implant in U.S. BREATHE Trial

      NYXH initiates its U.S. BREATHE study with the first Genio implant, advancing long-term clinical evidence following FDA approval.

      Sep 8Yahoo FinanceNYXH
      Nyxoah Announces First Patient Implanted in BREATHE, the U.S. Post-Approval Study of the Genio® System

      Nyxoah Announces First Patient Implanted in BREATHE, the U.S. Post-Approval Study of the Genio® System BREATHE is scheduled to implant up to 229 patients at up to 25 U.S. centers, followed for up to five years, to evaluate the long-term safety and effectiveness of the Genio therapy in real-world clinical practice First implant performed by Rolando Molina, MD, South Florida ENT Associates, with Edward Mezerhane, MD, of PharmaDev Clinical Research Institute as Site Principal Investigator Mont-Sain

      Sep 7Yahoo FinanceNYXH
      Cantor Fitzgerald reiterates Nyxoah stock rating on trial success
      Sep 4Investing.comNYXH
      Nyxoah stock rises on pivotal trial win for Genio (NYXH:NASDAQ)
      Sep 3Seeking AlphaNYXH
      Nyxoah stock surges as sleep apnea study hits endpoints
      Sep 3Investing.comNYXH
      Nyxoah Announces ACCCESS U.S. Pivotal Study Meets Primary Safety and Efficacy Endpoints in Complete Concentric Collapse Patients

      REGULATED INFORMATION INSIDE INFORMATION Nyxoah Announces ACCCESS U.S. Pivotal Study Meets Primary Safety and Efficacy Endpoints in Complete Concentric Collapse Patients Reports an Apnea-Hypopnea Index (AHI) responder rate of 77.2% on a Full Analysis Set basis (p<0.001) Zero device-related serious adverse events through 12 months Mont-Saint-Guibert, Belgium – September 2, 2026, 10:05 pm CET / 4:05 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technolog

      Sep 2Yahoo FinanceNYXH
      Information on the total number of voting rights and shares

      REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), August 25, 2026, 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issuance of 1,767,402 new shares on August 20, 2026 in connection with the contribution in kind of a receivable held by the holder of the convertible bon

      Aug 25Yahoo FinanceNYXH

      This is the newest page. Registered accounts read further back.